A current examine led by Asep Inc.’s Founder, Chair and CEO, Dr. Robert E. W. Hancock, concludes that there’s hope for improved scientific administration of COVID-19 sufferers by higher assessing the severity of sepsis, a virulent disease that impacts many COVID-19 sufferers.

VANCOUVER, BC, July 14, 2023 /CNW/ – Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is happy to announce the outcomes of a current scientific examine led by Asep Inc.’s Founder, Chair and CEO, Dr. Robert Hancock, that concluded that extreme COVID-19 is a type of sepsis primarily based on evaluation of blood gene expression signatures. Importantly, this examine highlights the potential advantages of a speedy diagnostic take a look at for sepsis, such because the Company’s Sepset^{ER (TM)} sepsis diagnostic take a look at, that might establish COVID-19 sufferers prone to growing extreme sepsis in addition to offering a path to a precision medication strategy to allow individualized therapy for the illness. Asep Inc. is an innovator on the entrance strains of sepsis analysis. In superior growth, the Company’s expertise may considerably profit the combat in opposition to sepsis in future pandemics, not simply COVID-19. The examine outcomes have been printed on January 23, 2023, within the scientific journal Scientific Reports.

The examine’s introduction states, “In the ongoing COVID-19 pandemic (2020 – 2022), it is increasingly evident that many of the millions of individuals who die with severe disease succumb due to sepsis, a life-threatening dysfunctional response to infection. In addition, the characterization of COVID-19 disease as a type of sepsis has important clinical implications for the prognosis and treatment of severely-afflicted COVID-19 patients.”¹ The examine analyzed the blood of 124 early (1–5 days post-hospital admission) and late (6–20 days post-hospital admission) sampled sufferers with confirmed COVID-19 infections from hospitals in Quebec, Canada.

Story continues

According to Dr. Hancock, “The results of this study can make a big difference to those treating the most severe and deadly cases of COVID-19 and emphasizes that severe COVID is essentially a form of severe sepsis. It also underscores the importance of early identification of sepsis in patients as they enter the emergency room. Our Sepset^ER test is fast, efficient and highly accurate at identifying those patients at the highest risk of progressing to severe sepsis. We are in the process of setting up subsequent clinical trials to demonstrate the utility of applying the Sepset^ER test on sepsis patients and identifying those patients at greatest risk of developing severe sepsis. The results of these clinical trials will be used to support our regulatory filings with the FDA to get the test cleared for use in hospitals.”

Asep Inc.’s Chief Scientific Officer Evan Haney commented, “Since sepsis is the major reason underlying the most severe consequences in every pandemic to date, the Sepset^ER test will also have an important role in future pandemics, identifying those patients who need treatment from those with mild or asymptomatic disease.”

The full scientific paper could be accessed right here www.nature.com/articles/s41598-023-28259-y

ABOUT ASEP MEDICAL HOLDINGS INC.

Asep Medical Holdings Inc. (asepmedical.com) is devoted to addressing the worldwide subject of antibiotic failure by growing novel options for vital unmet medical wants in human medication. The Company is a consolidation of three current non-public corporations, all with expertise in superior growth — Sepset Biosciences Inc. (proprietary diagnostic instruments to allow the early and well timed identification of sepsis), ABT Innovations Inc. (broad-spectrum therapeutic brokers to deal with multi-drug resistant biofilm infections), and SafeCoat Medical Inc. (an antibacterial peptide medical machine coating expertise).

Sepset Biosciences Inc. (sepset.ca) is within the last phases of preparation for scientific research and commercialization of an in vitro diagnostic take a look at that entails a affected person gene expression signature that helps assess the event of extreme sepsis, one of many vital ailments resulting in antibiotic failure since antibiotics are the first preliminary therapy for sepsis. Sepsis was answerable for practically 20% of all deaths on the planet in 2017 and basically all deaths resulting from COVID-19 and different pandemics. The Sepset^ER take a look at is a blood-based gene expression assay that’s simple to implement, and outcomes are obtained about an hour after taking a blood pattern within the emergency room or intensive care unit. This proprietary diagnostic expertise differs from present diagnostic checks, enabling the chance evaluation for development to extreme sepsis inside ~60 minutes of initiating the take a look at. Bacterial tradition, the gold normal, supplies outcomes after ~15 hours however could be so long as three days. Asep Inc. believes its take a look at will allow essential early choices to be made by physicians concerning applicable therapies and thus scale back total morbidity and mortality resulting from sepsis.

ABT Innovations Inc.’s (abtinnovations.ca) peptide expertise covers a broad vary of therapeutic functions, together with bacterial biofilm infections (dental, wound, sinusitis, pores and skin, medical machine infections, persistent infections, lung, bladder, ear-nose and throat, orthopaedic, and so forth.), anti-inflammatories, anti-infective immune-modulators and vaccine adjuvants. The firm is within the pre-clinical growth part with promising knowledge for the primary three indications.

SafeCoat Medical Inc.’s (safecoatmedical.com) expertise encompasses self-assembling polymers mixed with conjugated antimicrobial peptides, which could be utilized to numerous surfaces as antimicrobial and anti-fouling coatings. In explicit, the invention pertains to coatings which may be utilized to a number of medical units and implants, and feasibility has been demonstrated in animal fashions. The firm’s experience additionally encompasses the strategies for manufacturing and making use of these anti-bacterial coatings.

FORWARD-LOOKING STATEMENTS —

This information launch comprises sure “forward-looking statements” throughout the that means of such statements beneath relevant securities legislation. Forward-looking statements are incessantly characterised by phrases similar to “anticipates,” “plan,” “continue,” “expect,” “project,” “intend,” “believe,” “anticipate,” “estimate,” “may,” “will,” “potential,” “proposed,” “positioned” and different comparable phrases, or statements that sure occasions or situations “may” or “will” happen. These statements embrace however are usually not restricted to the profitable scientific testing of our Sepsis in vitro diagnostic take a look at and its meant submitting for regulatory market authorization; the Company not receiving regulatory market authorization as deliberate or in any respect; the endeavor of pre-clinical research on our lead therapeutic, with the expectation that it will result in fast-track scientific trials; the timeframe for identification of sepsis with the corporate’s merchandise; the potential alternatives for the technology of income; the therapeutic advantages of the corporate’s merchandise; and different statements concerning the corporate’s proposed enterprise plans. Various assumptions have been utilized in drawing conclusions or making the predictions contained within the forward-looking statements all through this information launch. Forward-looking statements are primarily based on the opinions and estimates of administration on the date the statements are made and are topic to a wide range of dangers together with the chance that the corporate’s merchandise might not carry out as anticipated; that the corporate might not obtain the requisite regulatory market authorization or outcomes of testing; the Company’s testing of the merchandise might not be profitable and market authorization might not be obtained within the estimated timelines or in any respect; the corporate might not be capable of generate income from its merchandise as anticipated or in any respect; the marketplace for the corporate’s merchandise might not be as described on this information launch; and varied different threat components recognized within the Asep Medical Inc.’s prospectus dated November 9, 2021, and within the firm’s administration dialogue and evaluation, obtainable for evaluate beneath the Company’s profile at www.sedar.com and uncertainties and different components that might trigger precise occasions or outcomes to vary materially from these projected within the forward-looking statements. Asep Medical Inc. is beneath no obligation and expressly disclaims any intention or obligation to replace or revise any forward-looking statements, whether or not because of new info, future occasions or in any other case, besides as expressly required by relevant legislation.

ENDNOTES

View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/another-breakthrough-asep-incs-ai-based-sepsis-technology-identifies-covid-19-severity-from-a-blood-sample-301877784.html

SOURCE ASEP Medical Holdings Inc.

View unique content material to obtain multimedia: http://www.newswire.ca/en/releases/archive/July2023/14/c8346.html